Categories Health Care, IPO, LATEST

IPO Alert: COVID-19 test maker Cue Health is all set to go public

The company's COVID-19 test, comprising a reader and test kit, is its first commercially available product

Just eight months into the year, IPO activity has already reached all-time highs, with tech firms and biotechnology startups leading the rally. Cue Health, Inc. is the latest healthcare company to join the IPO bandwagon, after registering strong revenue growth in recent months.   

$100 Mln IPO

The San Diego-headquartered provider of coronavirus test kits is preparing to list its shares on the Nasdaq Global Market under the ticker symbol HLTH. The company is looking to raise up to $100 million through the offering. The lead book-running managers for the offering are Goldman Sachs, Morgan Stanley, and Cowen. Meanwhile, the number of shares being offered and the offer price are not yet known.


What you need to know about Procept BioRobotics’ market debut


Cue Health’s COVID-19 test, comprising a reader and test kit, is its first commercially available test. According to the company, the portable test provides highly accurate, lab-quality results — detecting even emerging variants of the virus. The mobile app that supports the test, and linked to the Cue Health Monitoring System, is capable of delivering results within 30 minutes. The test is already used by enterprises, schools, clinics, and sports leagues in the U.S.

ipo news

In a connected healthcare ecosystem, such real-time data offered in portable form could significantly transform the way people manage their health. The diagnostics model, with a digital base, would help the company align well with the ongoing healthcare digital transformation and take its activities beyond diagnostics. Currently, it has more than100 patents in the portfolio, and the number is growing.

Global Reach

Recently, Indian regulators approved Cue health’s molecular point-of-care COVID-19 test for use in that country, on the heels of the company receiving international authorization for global health support in the European Union and securing interim order authorization in Canada.

Cue Health’s molecular diagnostic platform, which facilitates easy access to medical diagnostics, is the first of its kind available without a prescription. However, the company’s operation is not limited to coronavirus tests – currently, it is developing tests for other conditions in areas like respiratory health and women’s health. In order to meet the fund requirements, it raised $235 million in a private financing round in May.

Strong Topline Growth

In fiscal 2020, the company’s revenues more than tripled to about $23 million, aided by strong adoption of its COVID tests. The benefit from the top-line growth was more than offset by a sharp increase in operating expenses. As a result, net loss widened to $47.3 million or $2.90 per share from $20.6 million or $1.31 per share in fiscal 2019.


Read management/analysts’ comments on quarterly reports


Cue Health was founded more than a decade ago by Clint Sever and Ayub Khattak, who has served as the chief executive officer since then.  

Most Popular

Stitch Fix (SFIX) Stock: Will the innovative biz model survive virus-led slump?

The business world is still struggling to come out of the virus-induced slowdown, but it seems almost every retail segment benefited from the pandemic at some point. The vaccination drive

General Mills (GIS): Three factors that are expected to help drive growth for the food company going forward

Shares of General Mills Inc. (NYSE: GIS) were up 3.2% on Wednesday after the company delivered better-than-expected results for the first quarter of 2022. Net sales rose 4% year-over-year to

IPO Alert: Allvue Systems sets IPO terms, to raise around $290 million

It is estimated that the alternative investments industry has expanded at a compound annual rate of 10.2% over the past ten years and had $11 trillion in assets under management

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top